Catharine M Sturgeon

Summary

Affiliation: University of Edinburgh
Country: UK

Publications

  1. ncbi Practice guidelines for tumor marker use in the clinic
    Catharine Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, United Kingdom
    Clin Chem 48:1151-9. 2002
  2. ncbi Analytical error and interference in immunoassay: minimizing risk
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK
    Ann Clin Biochem 48:418-32. 2011
  3. ncbi Taking a new biomarker into routine use--a perspective from the routine clinical biochemistry laboratory
    Catharine Sturgeon
    Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Proteomics Clin Appl 4:892-903. 2010
  4. ncbi Perspectives in Clinical Proteomics Conference: translating clinical proteomics into clinical practice
    Catharine Sturgeon
    Department of Clinical Biochemistry, Edinburgh Royal Infirmary, Edinburgh, UK
    Expert Rev Proteomics 7:469-71. 2010
  5. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Clin Chem 56:e1-48. 2010
  6. ncbi Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary, Edinburgh, UK
    Clin Chem 55:1484-91. 2009
  7. ncbi National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Clin Chem 54:e11-79. 2008
  8. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Clin Chem 54:e1-e10. 2008
  9. ncbi Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, United Kingdom
    Clin Chim Acta 381:85-92. 2007
  10. ncbi Standardization of FSH, LH and hCG--current position and future prospects
    C M Sturgeon
    UK NEQAS for Peptide Hormones, Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK
    Mol Cell Endocrinol 260:301-9. 2007

Detail Information

Publications13

  1. ncbi Practice guidelines for tumor marker use in the clinic
    Catharine Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, United Kingdom
    Clin Chem 48:1151-9. 2002
    ..Increasing interest in implementing the practice of evidence-based medicine in oncology has encouraged the development of clinical guidelines, many of which include recommendations about the appropriate use of serum tumor markers...
  2. ncbi Analytical error and interference in immunoassay: minimizing risk
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK
    Ann Clin Biochem 48:418-32. 2011
    ....
  3. ncbi Taking a new biomarker into routine use--a perspective from the routine clinical biochemistry laboratory
    Catharine Sturgeon
    Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Proteomics Clin Appl 4:892-903. 2010
    ..Provision of measurements by a limited number of specialized reference laboratories may be most appropriate, especially when a new biomarker is first introduced into routine practice...
  4. ncbi Perspectives in Clinical Proteomics Conference: translating clinical proteomics into clinical practice
    Catharine Sturgeon
    Department of Clinical Biochemistry, Edinburgh Royal Infirmary, Edinburgh, UK
    Expert Rev Proteomics 7:469-71. 2010
    ..Some highlights from each of the three excellent conference sessions are described briefly here...
  5. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Clin Chem 56:e1-48. 2010
    ..Updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed...
  6. ncbi Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary, Edinburgh, UK
    Clin Chem 55:1484-91. 2009
    ....
  7. ncbi National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Clin Chem 54:e11-79. 2008
    ..Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed...
  8. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, UK
    Clin Chem 54:e1-e10. 2008
    ..This report presents updated National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines summarizing quality requirements for the use of tumor markers...
  9. ncbi Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh, EH16 4SA, United Kingdom
    Clin Chim Acta 381:85-92. 2007
    ..Commutability of immunoassay test results is an important objective for laboratory medicine...
  10. ncbi Standardization of FSH, LH and hCG--current position and future prospects
    C M Sturgeon
    UK NEQAS for Peptide Hormones, Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK
    Mol Cell Endocrinol 260:301-9. 2007
    ..Encouraging manufacturers to standardize and carefully describe the evaluation methods they use, such that data from different manufacturers can readily be compared, is also a pre-requisite for future progress...
  11. ncbi Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease
    Catharine M Sturgeon
    Correspondence and offprint requests to Catharine Sturgeon E mail
    Nephrol Dial Transplant 26:3440-5. 2011
    ..Concurrently, evidence-based recommendations on clinical requirements and performance goals for PTH are required. Improving the comparability of PTH results requires support from many stakeholders but is achievable...
  12. ncbi The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory
    Catharine M Sturgeon
    Department of Clinical Biochemistry, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK
    Ann Clin Biochem 48:295-9. 2011
    ..Continuous audit of the outcomes will also be essential to determine the effectiveness of this approach to early detection of ovarian cancer...
  13. ncbi National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers
    Eleftherios P Diamandis
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Chem 54:1935-9. 2008